Back to discover

Protein / target

Dual specificity mitogen-activated protein kinase kinase 1

Encoded byMAP2K1Q02750Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
8
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Mitogen-activated protein kinase kinase kinase binding

Strongest disease association

RASopathy

Via encoding gene MAP2K1 · Genetic evidence · score 0.94

Therapeutic position

Established drug target

Small molecules

Research activity

Emerging research

1 papers · latest 2012

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway.

View complete UniProt function annotation

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126). Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis

Subcellular location

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, spindle pole bodyCytoplasmNucleusMembrane
Domains and Gene Ontology detail (71)

Domains & features

Protein kinase

Gene Ontology

  • Caxon
  • Ccell cortex
  • Ccentrosome
  • Cciliary basal body
  • Ccytosol
  • Cdendrite cytoplasm
  • Cearly endosome
  • Cendoplasmic reticulum
  • Cfocal adhesion
  • Cglutamatergic synapse
  • CGolgi apparatus
  • Clate endosome

393 aa · 43 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOReceptor tyrosine kinase signallingGOGrowth-factor signallingGOCell proliferation & survivalGOLipid & lipoprotein metabolismGONuclear receptor signallingUniProt
View supporting evidence

Cell migration

  • ·chemotaxis
  • ·positive regulation of cell migration

Receptor tyrosine kinase signalling

  • ·ERBB2-ERBB3 signaling pathway

Growth-factor signalling

  • ·insulin-like growth factor receptor signaling pathway

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

Lipid & lipoprotein metabolism

  • ·triglyceride homeostasis

Nuclear receptor signalling

  • ·Dual specificity protein kinase which acts as an essential component of the MAP kinase s…
View underlying pathways (15)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

MAPK3BRAFMAPK1RAF1LAMTOR3KSR2KSR1MAP2K2KRASARAFMAP2K1

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

3 medicines · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Melanoma1 medicine

8 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

3

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

binimetinib
Narrow target profileApprovedInhibitor

Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Indicated for Melanoma, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

cobimetinib
Narrow target profileApprovedInhibitor

Dual specificity mitogen-activated protein kinase kinase 1 inhibitor

Indicated for Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

trametinib
ApprovedInhibitor

Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor

Indicated for Neoplasms

Acts on a complex — shared with MAP2K2 · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MAP2K1

Gene-level evidence surfaced through the gene MAP2K1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

RASopathy
0.95Well supported

Genetic evidence dominant · Open Targets 0.60

Melorheostosis
0.93Well supported

Genetic evidence dominant · Open Targets 0.72

Noonan syndrome
0.92Well supported

Genetic evidence dominant · Open Targets 0.67

Cardiofaciocutaneous syndrome 3
0.91Well supported

Genetic evidence dominant · Open Targets 0.81

Cardiofaciocutaneous syndrome
0.90Well supported

Genetic evidence dominant · Open Targets 0.83

View evidence synthesis (5)
RASopathyWell supported
0.95
agreement 0.811.00
Genetic90%Literature11%

Open Targets aggregate 0.60 · 2 independent evidence families

MelorheostosisWell supported
0.93
agreement 0.821.00
Genetic60%Somatic mutation34%Literature6%Genetic literaturedup

Open Targets aggregate 0.72 · 3 independent evidence families · 1 not counted as duplicate

Noonan syndromeWell supported
0.92
agreement 0.831.00
Genetic60%Pathway25%Animal model8%Clinical7%Literature1%Genetic literaturedup

Open Targets aggregate 0.67 · 5 independent evidence families · 1 not counted as duplicate

Cardiofaciocutaneous syndrome 3Well supported
0.91
agreement 0.771.00
Genetic99%Literature1%Genetic literaturedup

Open Targets aggregate 0.81 · 2 independent evidence families · 1 not counted as duplicate

Cardiofaciocutaneous syndromeWell supported
0.90
agreement 0.781.00
Genetic70%Pathway25%Literature5%Genetic literaturedup

Open Targets aggregate 0.83 · 3 independent evidence families · 1 not counted as duplicate

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Cardiofaciocutaneous syndrome0.83
Cardiofaciocutaneous syndrome 30.81
Melanoma0.73
Melorheostosis0.72
Neoplasms0.69
Noonan syndrome0.67
RASopathy0.60
Neurofibromatosis 10.57
Noonan syndrome with multiple lentigines0.55

Drug development

19 compounds recorded · 8 approved · 11 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 3 drugs that target this protein in Forefront's canonical graph (3 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
MIRDAMETINIBApproval
REFAMETINIBPhase 3
TRAMETINIB DIMETHYL SULFOXIDEApproval
PIMASERTIBPhase 2
CI-1040Phase 2
E-6201Phase 2
TAK-733Phase 2
BINIMETINIBApproval
COBIMETINIBApproval
AZD-8330Phase 1

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (literature and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (12)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · High-Quality PocketSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · Human Protein Atlas locPR · LiteraturePR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

ACTIVE_NOT_RECRUITING · via binimetinib · NCT05554367

View all trials (26)

RECRUITING · via trametinib · NCT07477457

RECRUITING · via trametinib · NCT06119789

ACTIVE_NOT_RECRUITING · via binimetinib · NCT05170334

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-08-20

    Label change: COBIMETINIB (NDA206192)

    fda · regulatory · fda · via cobimetinib

  2. Trial status changed2026-07-22

    Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

    Status changed to Terminated · ClinicalTrials.gov · via trametinib

  3. Trial status changed2026-05-05

    Phase 1b Study of IDH Inhibition With Enasidenib and MEK Inhibition With Cobimetinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

    Status changed to Completed · ClinicalTrials.gov · via cobimetinib

  4. New publication2024-09-23
    Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

    Nature medicine · 2024 · 52 citations · Europe PMC · via binimetinib

  5. Regulatory approval2024-01-05

    Approval: Spexotras (EMA)

    ema · regulatory · ema · via trametinib

  6. Label change2023-05-31

    Label change: COBIMETINIB (NDA206192)

    fda · regulatory · fda · via cobimetinib

  7. Indication expanded2022-10-28

    Indication expansion: COBIMETINIB (NDA206192)

    fda · regulatory · fda · via cobimetinib

  8. New publication2022-09-27
    Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 302 citations · Europe PMC · via trametinib

  9. Indication expanded2022-07-28

    Indication expansion: COBIMETINIB (NDA206192)

    fda · regulatory · fda · via cobimetinib

  10. New publication2019-09-30
    Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.

    The New England journal of medicine · 2019 · 1,029 citations · Europe PMC · via binimetinib

  11. Safety communication2016-03-10

    Drug Safety Update: Trametinib (Mekinist▼): risk of gastrointestinal perforation and colitis

    mhra · safety · mhra · via trametinib

  12. New publication2014-11-16
    Improved overall survival in melanoma with combined dabrafenib and trametinib.

    The New England journal of medicine · 2015 · 1,914 citations · Europe PMC · via trametinib

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.

Research activity

1 papers · to 2012

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Flaherty KT · The New England journal of medicine · 2012

Recent

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Flaherty KT · The New England journal of medicine · 2012

Europe PMC papers linked directly to this protein.

Related family literature

11

Papers about “Mitogen-Activated Protein Kinase Kinases” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.

Atkins MB · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023

via Mitogen-Activated Protein Kinase Kinases

CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.

Kohlmeyer JL · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

via Mitogen-Activated Protein Kinase Kinases

Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.

Chaudagar K · Clinical cancer research : an official journal of the American Association for Cancer Research · 2023

via Mitogen-Activated Protein Kinase Kinases

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.

Bahar ME · Signal transduction and targeted therapy · 2023

via Mitogen-Activated Protein Kinase Kinases

Inflammation and tumor progression: signaling pathways and targeted intervention.

Zhao H · Signal transduction and targeted therapy · 2021

via Mitogen-Activated Protein Kinase Kinases

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Erkes DA · Cancer discovery · 2020

via Mitogen-Activated Protein Kinase Kinases

Pediatric low-grade glioma in the era of molecular diagnostics.

Ryall S · Acta neuropathologica communications · 2020

via Mitogen-Activated Protein Kinase Kinases

Phase separation of signaling molecules promotes T cell receptor signal transduction.

Su X · Science (New York, N.Y.) · 2016

via Mitogen-Activated Protein Kinase Kinases

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert C · The New England journal of medicine · 2015

via Mitogen-Activated Protein Kinase Kinases

Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.